{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:38:49Z","timestamp":1794663529995,"version":"4.9.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Most patients with acute myeloid leukemia (AML) may obtain remission upon induction chemotherapy, but relapse is frequent and associated with poor survival. Previous prognostic models for outcomes after relapse lacked analysis of comprehensive molecular data. A validated prognostic model integrating clinical, cytogenetic, and molecular variables may support treatment decisions. We studied 943 patients with AML who relapsed after intensive induction treatment in a development cohort (HOVON-SAKK). A random survival forest algorithm was used to evaluate the association of clinical parameters, cytogenetic abnormalities, and molecular variables at diagnosis with overall survival (OS). Relapsing patients (n = 377) who were enrolled in the NCRI-AML18 trial were used for validation. In the development cohort, the median age at relapse was 58 years, and patients were classified as 2022 European LeukemiaNet favorable (22%), intermediate (31%), and adverse risk (48%). One-third underwent allogeneic transplantation in the first complete remission. Variable selection yielded 9 variables associated with 1-year OS, including relapse-free interval, age, white blood cell count, mutated TP53, FLT3 internal tandem duplication, core-binding factor abnormalities, t(v;11q23)\/KMT2A rearrangement, and complex\/monosomal karyotype, which were assigned points according to their estimated hazard ratios. Three prognostic groups were defined with distinct 1-year OS in both development (favorable, 51% \u00b1 3%; intermediate, 29% \u00b1 3%; and poor, 14% \u00b1 2%, respectively) and validation cohorts (51% \u00b1 4%, 26% \u00b1 5%, and 14% \u00b1 3%, respectively). Validation confirmed the improved accuracy in predicting outcomes for patients with AML in first relapse. The revised AML relapse model improved on previous prognostic models for outcomes after first relapse. It provides stratification that might support tailoring second line treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015797","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T09:50:22Z","timestamp":1747907422000},"page":"3853-3864","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["A revised prognostic model for patients with acute myeloid leukemia and first relapse"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9751-8122","authenticated-orcid":false,"given":"Niek G.","family":"van der Maas","sequence":"first","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Breems","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Ziekenhuis aan de Stroom, Cadix Hospital, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara P. W.","family":"Klerk","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Dijklander Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, University Hospital, Inselspital, Bern, Switzerland"},{"name":"5Swiss Group for Clinical Cancer Research, SAKK, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4620-9163","authenticated-orcid":false,"given":"Patrycja","family":"Gradowska","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands"},{"name":"6HOVON Foundation, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-6762","authenticated-orcid":false,"given":"Abin","family":"Thomas","sequence":"additional","affiliation":[{"name":"7Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-5743","authenticated-orcid":false,"given":"Bart J.","family":"Biemond","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Amsterdam University Medical Center, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-7806","authenticated-orcid":false,"given":"Jurgen","family":"Kuball","sequence":"additional","affiliation":[{"name":"9Department of Hematology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina H. M. J.","family":"Van Elssen","sequence":"additional","affiliation":[{"name":"10Division Hematology, Department of Internal Medicine, GROW institute for Oncology and developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Isala Hospital, Zwolle, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christiane","family":"Vekemans","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9236-3623","authenticated-orcid":false,"given":"Carlos","family":"Graux","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Universit\u00e9 Catholique de Louvain, University Hospital Center Namur (Godinne), Yvoir, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"14Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-4441","authenticated-orcid":false,"given":"Steven","family":"Knapper","sequence":"additional","affiliation":[{"name":"15School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-8673","authenticated-orcid":false,"given":"Mike","family":"Dennis","sequence":"additional","affiliation":[{"name":"16Department of Haematology, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie","family":"Freeman","sequence":"additional","affiliation":[{"name":"17Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Thomas","sequence":"additional","affiliation":[{"name":"7Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-7617","authenticated-orcid":false,"given":"H. Berna","family":"Beverloo","sequence":"additional","affiliation":[{"name":"18Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[{"name":"19Department of Hematology, University Medical Center, University Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-6678","authenticated-orcid":false,"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[{"name":"20Warwick Clinical Trials Unit, University of Warwick, Warwick, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J. M.","family":"Valk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-0914","authenticated-orcid":false,"given":"Paresh","family":"Vyas","sequence":"additional","affiliation":[{"name":"21MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"22Department of Haematology, Oxford University Hospitals NHS Trust and Oxford Biomedical Centre, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[{"name":"23Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Amsterdam University Medical Center, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-5217","authenticated-orcid":false,"given":"Bob","family":"L\u00f6wenberg","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1663","authenticated-orcid":false,"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"9","key":"2025081209513415300_bib1","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025081209513415300_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"2025081209513415300_bib3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025081209513415300_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","article-title":"Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"2025081209513415300_bib5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"2025081209513415300_bib6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2025081209513415300_bib7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"2025081209513415300_bib8","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory -mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"7954","key":"2025081209513415300_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"9","key":"2025081209513415300_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"DeWolf","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2025081209513415300_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025081209513415300_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.1988.6.2.232","article-title":"The characteristics and outcome of patients with late relapse acute myelogenous leukemia","volume":"6","author":"Kantarjian","year":"1988","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025081209513415300_bib13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1989.7.8.1071","article-title":"Response to salvage therapy and survival after relapse in acute myelogenous leukemia","volume":"7","author":"Keating","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025081209513415300_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/joim.12720","article-title":"Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia","volume":"283","author":"Craddock","year":"2018","journal-title":"J Intern Med"},{"issue":"34","key":"2025081209513415300_bib15","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.23.02631","article-title":"Risk stratification in older intensively treated patients with AML","volume":"42","author":"Versluis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025081209513415300_bib16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa025406","article-title":"Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia","volume":"349","author":"L\u00f6wenberg","year":"2003","journal-title":"N Engl J Med"},{"issue":"13","key":"2025081209513415300_bib17","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"L\u00f6wenberg","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2025081209513415300_bib18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"L\u00f6wenberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"31","key":"2025081209513415300_bib19","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025081209513415300_bib20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood-2016-10-740613","article-title":"Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML","volume":"129","author":"L\u00f6wenberg","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2025081209513415300_bib21","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41375-020-0725-0","article-title":"Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS","volume":"34","author":"Ossenkoppele","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2025081209513415300_bib22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/bloodadvances.2020003855","article-title":"Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial","volume":"5","author":"L\u00f6wenberg","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2025081209513415300_bib23","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41375-022-01657-3","article-title":"Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome","volume":"36","author":"Janssen","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2025081209513415300_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2025081209513415300_bib25","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025081209513415300_bib26","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"issue":"23","key":"2025081209513415300_bib27","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2025081209513415300_bib28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.1985.3.7.992","article-title":"High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia","volume":"3","author":"Herzig","year":"1985","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025081209513415300_bib29","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.1991.9.7.1210","article-title":"Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia","volume":"9","author":"Amadori","year":"1991","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025081209513415300_bib30","first-page":"1847","article-title":"A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial","volume":"8","author":"Vogler","year":"1994","journal-title":"Leukemia"},{"issue":"4","key":"2025081209513415300_bib31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","article-title":"Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia","volume":"99","author":"Parker","year":"1997","journal-title":"Br J Haematol"},{"issue":"1","key":"2025081209513415300_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajh.25333","article-title":"A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease","volume":"94","author":"Litzow","year":"2019","journal-title":"Am J Hematol"},{"issue":"9","key":"2025081209513415300_bib33","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s00432-021-03821-1","article-title":"Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy","volume":"148","author":"M\u00fchleck","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2025081209513415300_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough?","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers"},{"key":"2025081209513415300_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis","volume":"12","author":"Kwag","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025081209513415300_bib36","doi-asserted-by":"crossref","first-page":"1370405","DOI":"10.3389\/fonc.2024.1370405","article-title":"Efficacy and safety of venetoclax plus hypomethylating agents in relapsed\/refractory acute myeloid leukemia: a multicenter real-life experience","volume":"14","author":"Angotzi","year":"2024","journal-title":"Front Oncol"},{"key":"2025081209513415300_bib37","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv"},{"key":"2025081209513415300_bib38","author":"Atluri","year":"2023\/12\/11"},{"key":"2025081209513415300_bib39","author":"Briski","year":"2023\/12\/10"},{"key":"2025081209513415300_bib40","author":"Yilmaz","year":"2023\/12\/9"},{"key":"2025081209513415300_bib41","author":"Al-Shaibani","year":"2024"},{"issue":"10","key":"2025081209513415300_bib42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2025081209513415300_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/leu.2014.164","article-title":"Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission","volume":"29","author":"Versluis","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2025081209513415300_bib44","doi-asserted-by":"crossref","first-page":"e846","DOI":"10.1097\/HS9.0000000000000846","article-title":"Prediction of nonrelapse mortality in patients with acute myeloid leukemia and acute lymphoblastic leukemia receiving allogeneic stem cell transplantation with posttransplantation cyclophosphamide-based graft versus host disease prophylaxis","volume":"7","author":"Hermans","year":"2023","journal-title":"HemaSphere"},{"issue":"5","key":"2025081209513415300_bib45","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8041","key":"2025081209513415300_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"8","key":"2025081209513415300_bib47","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"2025081209513415300_bib48","unstructured":"HOVON. Survival prediction for patients with AML and first relapse. 2024. Accessed 25 June 2025. https:\/\/hovon-aml.shinyapps.io\/AML_Relapse_Score\/."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3853\/2404580\/blooda_adv-2025-015797-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3853\/2404580\/blooda_adv-2025-015797-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:51:44Z","timestamp":1755006704000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3853\/537378\/A-revised-prognostic-model-for-patients-with-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":48,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015797","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,28]]}}}